Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.
Doctors are increasingly fighting cancer by stimulating patients' immune systems. SNSF-supported researchers have now discovered a method for predicting the likelihood of treatment success.
President Donald Trump wants to control spending on drugs. One of his big ideas: include prices in advertisements, just like warnings about side effects.
Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.
The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.
A team led by Dr Edmond Ma Dik-lung, Associate Professor of the Department of Chemistry of Hong Kong Baptist University has developed the world's first iridium(III)-based probes for imaging dopamine receptors in living cells.
The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive).
Very small differences in the way a patient lies during radiotherapy treatment for lung or oesophageal cancer can have an impact on how likely they are to survive, according to research presented at the ESTRO 37 conference.
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.
Lung cancer often metastasizes to the brain. Historically, brain metastases have been treated with whole-brain radiation therapy.
Researchers from UCLA and Long Beach Memorial Medical Center have found that two targeted therapies could be more effective if used in combination to treat squamous cell carcinomas of the lung.
The most common type of lung cancer, non-small cell lung cancer (NSCLC), continues to be difficult to treat, with five year survival rates of about 36 percent for stage 3A tumors.
Research by Rutgers Cancer Institute of New Jersey investigators has identified novel functions of the superoxide dismutase 1 (SOD1) enzyme providing support that it could serve as a therapeutic target in the most common type of lung cancer.
The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation).
In recent years, a powerful suite of drugs known as kinase inhibitors have been developed to treat cancer and other diseases. Primary targets of such drugs include a family of receptor tyrosine kinases (RTKs) which protrude from cell surfaces like antennae and can activate cancer-related pathways in virtually all types of cancer when signaling molecules bind with them.
One small molecule that helps regulate gene expression plays a big role in keeping us safe from the machinations of cancer, scientists report.
Lung cancer treatment often pairs targeted therapies with genetic alterations driving the disease. This makes detecting these genetic alterations an essential step in diagnosis.
Elderly patients with stage III non-small cell lung cancer showed improved overall survival when treated with chemoradiation compared to definitive radiation alone.
Simple blood tests can reveal a great deal about a person's health. They can uncover infection, anemia, diabetes and high cholesterol and provide clues about many other conditions.
An urgent question for cancer scientists is why immunotherapy achieves dramatic results in some cases but doesn't help most patients.
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management of non-metastatic small-cell lung cancer (SCLC), a large percentage of U.S. patients do not receive these treatments and in turn have lower overall survival, according to research from The University of Texas MD Anderson Cancer Center.